Two series of HIV protease inhibitors possessing a hydroxyaminopentana
mide transition state isostere were prepared and evaluated in peptide
cleavage and whole cell assays. These were found to be effective in lo
w concentrations at halting the spread of the AIDS virus, and a number
of these inhibitors were also found to provide reasonable plasma leve
ls after oral The most promising, L-748,496 is potent (IC50 = 0.12 nM
and IC95 = 6-12 nM) and comparable to L-735,524 which is currently in
phase II human clinical trials.